Seer (SEER) TD Cowen 45th Annual Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 45th Annual Healthcare Conference summary
2 Dec, 2025Medicaid policy and regulatory environment
Current federal budget proposals include significant Medicaid reduction figures, but most proposed cuts are unlikely to pass and would not materially impact the business due to exemptions and the company's low-cost provider status.
Work requirements in Medicaid could benefit recruitment, as the company offers flexible, part-time roles that align with new workforce entrants.
The patient base is largely insulated from work requirements due to age and disability exemptions, minimizing risk of coverage loss.
Redeterminations slowed new patient intake, especially in Illinois, but did not result in significant patient loss; new patient flow is beginning to recover.
State and federal lobbying efforts continue, with little concern about imminent regulatory threats.
Financial performance and outlook
A 5.5% rate increase in Illinois, the largest market, is expected to drive top-end same-store growth in personal care, targeting 3%-5% for the year.
Hospice segment, about 20% of business, is seeing early momentum with anticipated 2.5%-3% rate increases and volume growth.
Seasonal margin patterns persist, with Q1 as the low point and Q4 benefiting from hospice rate increases and payroll tax relief.
M&A remains a focus, with the Gentiva acquisition integrated and further deals, especially smaller tuck-ins, considered accretive and likely.
EBITDA outlook for 2025 is based on stripping out New York, adding Gentiva, and applying same-store growth metrics.
Gentiva acquisition and integration
Cultural fit and operational alignment with Gentiva's PCS business have been strong, aided by extensive pre-close planning.
Early integration focused on payroll and financial reporting, with leadership training and data-driven decision-making introduced.
Gentiva is scheduled for EMR system conversion in about 18 months, with current systems maintained until then.
Financial and transition goals have been met, and the acquisition is viewed as successful to date.
Latest events from Seer
- Strong growth, innovation, and new detector tech set the stage for future expansion.SEER
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 17% to $16.6M, with improved margins and a 67% increase in installed base.SEER
Q4 202526 Feb 2026 - Q2 revenue fell 23% to $3.1M; guidance cut, but cash remains strong and pipeline is growing.SEER
Q2 20242 Feb 2026 - High-impact publications and scientific validation drive optimism for growth in 2025.SEER
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Proteograph's robust, scalable platform accelerates unbiased biomarker discovery and scientific adoption.SEER
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue fell 3% to $4.0M; net loss was $21.3M; new Thermo Fisher partnership announced.SEER
Q3 202416 Jan 2026 - Proteograph's scale and partnerships are accelerating unbiased proteomics adoption and discovery.SEER
Guggenheim Securities Inaugural Healthcare Innovation Conference15 Jan 2026 - Accelerating global adoption and innovation in deep proteomics drive strong 2025 outlook.SEER
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2025 revenue is guided to grow 24% to $17–18M, with gross margin expected at 50–53%.SEER
Q4 202424 Dec 2025